Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses an interim analysis of the GMMG-CONCEPT trial (NCT03104842), which investigated depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).